MedWatch’s Patient-friendly Reporting Form Might Need An Overhaul
This article was originally published in The Pink Sheet Daily
Executive Summary
Promotion of the consumer MedWatch form needs to be improved if more physicians and consumers are to use it, FDA’s Risk Communications Advisory Committee says.
You may also be interested in...
EU ADR App To Underpin Region’s Regulatory Approach To Social Media
EU regulators are set to launch an adverse drug reaction reporting app in March and will follow this up with a social media monitoring drive to improve pharmacovigilance.
FDA’s Social Media Messages Should Be Pretested, Risk Communication Advisors Say
Risk Communication Advisory Committee members express support for FDA’s social media plans, but emphasize the importance of pretesting messages and studying the impact of agency efforts.
CDRH Details Path Forward For National Post-Market Surveillance System
The device center released an updated plan for post-market surveillance reforms, featuring a planning board that will establish a governing structure for the new system, as well as implementation dates for various post-market projects.